Beacon to develop right-to-try patient match platform

Beacon Pharmaceutical (New York, N.Y.) said it will launch a new platform to connect terminally ill patients with experimental therapies under the new right-to-try law.

The firm is developing the platform as a philanthropic effort through its venture Beacon Capital arm, which has dedicated $5 million to develop a patient portal with information about accessing the experimental treatments at local institutions...